Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.
Аннотация
PURPOSE: To provide a reference for healthcare organizations in the selection and rational use of ALK inhibitors, based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the Second Edition).
METHODS
According to the 2nd edition of China's drug evaluation and selection guideline released in 2023, relevant databases such as PubMed, Micromedex, and Medlive, drug labels, and clinical guidelines were searched for specific drug information. We systematically evaluated eight ALK inhibitors marketed in China for pharmacological properties, efficacy, safety, economy, and other attributes using a percentage scoring method.
RESULTS
The ranking of ALK inhibitors was derived from a structured scoring framework based on the 2nd Edition of China's Drug Evaluation and Selection Guideline. The final assessment result scores from highest to lowest were alectinib (78.70 points), lorlatinib (78.70 points), brigatinib (78.50 points), ensartinib (73.30 points), iruplinalkib (72.55 points), ceritinib (71.50 points), envonalkib (71.15 points), crizotinib (70.60 points).
CONCLUSION
Based on the second edition of China's drug evaluation and selection guideline and combined with the clinical application characteristics of ALK inhibitors, this study performed a multidimensional scoring of eight ALK inhibitors. The evaluation results could provide a reference for medical institutions in the introduction and elimination of ALK inhibitors.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.